{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:22:19Z","timestamp":1790706139787,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejmg.2022.104672","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T20:33:53Z","timestamp":1669062833000},"page":"104672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["An update on molecular features and therapeutic perspectives of pediatric classical Hodgkin Lymphoma. What the clinician needs to know?"],"prefix":"10.1016","volume":"66","author":[{"given":"Mathieu","family":"Simonin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Leblanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Landman Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmg.2022.104672_bib1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17719","article-title":"Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping","volume":"195","author":"Alcoceba","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2022.104672_bib2","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2019.03.002","article-title":"Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency","volume":"144","author":"Alosaimi","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmg.2022.104672_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib5","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmg.2022.104672_bib6","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ejmg.2022.104672_bib7","first-page":"32207","article-title":"Classical Hodgkin lymphoma","volume":"S0140\u20136736","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmg.2022.104672_bib8","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study Group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2022.104672_bib10","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib12","article-title":"Nivolumab and brentuximab vedotin (BV)-based, response-adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed\/refractory classical Hodgkin lymphoma (R\/R cHL): primary analysis","volume":"38","author":"Cole","year":"2020","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmg.2022.104672_bib13","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib14","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1038\/ncomms4856","article-title":"A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus","volume":"5","author":"Cozen","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmg.2022.104672_bib15","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1097\/HS9.0000000000000329","article-title":"Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet pediatric Hodgkin lymphoma Group","volume":"4","author":"Daw","year":"2020","journal-title":"Hemasphere"},{"key":"10.1016\/j.ejmg.2022.104672_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2022.104672_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/path.1454","article-title":"Inactivating I kappa B epsilon mutations in Hodgkin\/Reed-Sternberg cells","volume":"201","author":"Emmerich","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmg.2022.104672_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/ng.696","article-title":"A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)","volume":"42","author":"Enciso-Mora","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmg.2022.104672_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1182\/blood.2020007900","article-title":"How I incorporate novel agents into the treatment of classical Hodgkin lymphoma","volume":"138","author":"Epperla","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib20","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/ncomms3549","article-title":"Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin's lymphoma","volume":"4","author":"Frampton","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmg.2022.104672_bib21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fimmu.2018.00979","article-title":"Interleukin-2-Inducible T-cell kinase deficiency-new patients, new insight?","volume":"9","author":"Ghosh","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmg.2022.104672_bib22","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1182\/blood.2020006738","article-title":"Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency","volume":"136","author":"Ghosh","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib23","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib24","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmg.2022.104672_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma","volume":"14","author":"Guo","year":"2016","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib26","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.3324\/haematol.12875","article-title":"Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization","volume":"93","author":"Hartmann","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmg.2022.104672_bib27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/bjh.14311","article-title":"Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma","volume":"175","author":"Herrera","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2022.104672_bib28","first-page":"3435","article-title":"Association between glutathione S-transferase genotypes and hodgkin's lymphoma risk and prognosis","volume":"9","author":"Hohaus","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmg.2022.104672_bib29","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1182\/bloodadvances.2017006346","article-title":"High proportions of PD-1+ and PD-L1+ leukocytes in classical Hodgkin lymphoma microenvironment are associated with inferior outcome","volume":"1","author":"Hollander","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmg.2022.104672_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20160784","article-title":"Inherited CD70 deficiency in humans reveals a critical role for the CD70-CD27 pathway in immunity to Epstein-Barr virus infection","volume":"214","author":"Izawa","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib31","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/jcp.2007.050146","article-title":"Contribution of the Epstein\u2013Barr virus to the molecular pathogenesis of Hodgkin lymphoma","volume":"60","author":"Kapatai","year":"2007","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.ejmg.2022.104672_bib32","article-title":"Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients","author":"Karihtala","year":"2021","journal-title":"Blood Adv. bloodadvances"},{"key":"10.1016\/j.ejmg.2022.104672_bib33","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1182\/blood-2015-04-639781","article-title":"Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries","volume":"126","author":"Kharazmi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1053\/j.semnuclmed.2017.01.001","article-title":"Current role of FDG-PET in pediatric hodgkin's lymphoma","volume":"47","author":"Kluge","year":"2017","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib35","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"K\u00fcppers","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmg.2022.104672_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ijc.24502","article-title":"Mutations of NFKBIA, encoding IkappaB alpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases","volume":"125","author":"Lake","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmg.2022.104672_bib37","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fimmu.2018.01103","article-title":"Inherited immunodeficiencies with high predisposition to epstein\u2013barr virus-driven lymphoproliferative diseases","volume":"9","author":"Latour","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmg.2022.104672_bib38","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/leu.2011.371","article-title":"Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseases","volume":"26","author":"Linka","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2022.104672_bib39","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.3390\/cancers13194752","article-title":"Epstein\u2013barr virus in inborn immunodeficiency\u2014more than infection","volume":"13","author":"Lino","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmg.2022.104672_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28562","article-title":"Pediatric classical Hodgkin lymphoma","volume":"68","author":"Lo","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejmg.2022.104672_bib41","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S2352-3026(18)30153-4","article-title":"Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1\/2 study","volume":"5","author":"Locatelli","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejmg.2022.104672_bib42","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.1997.15.11.3338","article-title":"Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease","volume":"15","author":"Longo","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib43","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1182\/blood-2005-06-2341","article-title":"Rescue of \u201ccrippled\u201d germinal center B cells from apoptosis by Epstein-Barr virus","volume":"106","author":"Mancao","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib44","doi-asserted-by":"crossref","first-page":"ix96","DOI":"10.1093\/annonc\/mdz427.018","article-title":"Phase II, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667","volume":"30","author":"Mauz-koerholz","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib45","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2009.26.9381","article-title":"Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study","volume":"28","author":"Mauz-K\u00f6rholz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(21)00470-8","volume":"23","author":"Mauz-K\u00f6rholz","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib47","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bjh.15203","article-title":"Germline mutations in Protection of Telomeres 1 in two families with Hodgkin lymphoma","volume":"181","author":"McMaster","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2022.104672_bib48","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1200\/JCO.20.03286","article-title":"Excellent outcome for pediatric patients with high-risk Hodgkin lymphoma treated with brentuximab vedotin and risk-adapted residual node radiation","volume":"39","author":"Metzger","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib49","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejmg.2022.104672_bib50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","author":"Oki","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmg.2022.104672_bib51","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000002403","article-title":"Epstein-barr virus in childhood and adolescent classic Hodgkin lymphoma in a French cohort of 301 patients","author":"Pereira","year":"2022","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib52","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","article-title":"US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging: southwest oncology Group S0816","volume":"34","author":"Press","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib53","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7150\/jca.13593","article-title":"Kinetics of circulating plasma cell-free DNA in paediatric classical Hodgkin lymphoma","volume":"7","author":"Primerano","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmg.2022.104672_bib54","first-page":"1997","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmg.2022.104672_bib55","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1172\/JCI131116","article-title":"Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease","volume":"130","author":"Ravell","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmg.2022.104672_bib56","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib57","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1084\/jem.20190678","article-title":"Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells","volume":"216","author":"Rodriguez","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib58","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib59","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2011-03-341560","article-title":"Exome sequencing reveals germline NPAT mutation as a candidate risk factor for Hodgkin lymphoma","volume":"118","author":"Saarinen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib60","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.0904231106","article-title":"Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells","author":"Salipante","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmg.2022.104672_bib61","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3389\/fimmu.2018.02400","article-title":"EBV negative lymphoma and autoimmune lymphoproliferative syndrome like phenotype extend the clinical spectrum of primary immunodeficiency caused by STK4 deficiency","volume":"9","author":"Schipp","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmg.2022.104672_bib62","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib63","first-page":"1171","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.ejmg.2022.104672_bib64","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1182\/blood.2019000644","article-title":"CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis","volume":"134","author":"Somekh","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib65","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fbioe.2020.00179","article-title":"Identification of familial Hodgkin lymphoma predisposing genes using whole genome sequencing","volume":"8","author":"Srivastava","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ejmg.2022.104672_bib67","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic hodgkin's lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmg.2022.104672_bib68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1182\/blood-2009-12-257345","article-title":"Genome-wide copy number analysis of Hodgkin Reed-Sternberg cells identifies recurrent imbalances with correlations to treatment outcome","volume":"116","author":"Steidl","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib69","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib70","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.2019000928","article-title":"Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection","volume":"135","author":"Tangye","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib71","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1200\/JCO.2008.16.0861","article-title":"Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review","volume":"27","author":"Terasawa","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmg.2022.104672_bib72","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2017-11-814913","article-title":"Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma","volume":"131","author":"Tiacci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmg.2022.104672_bib73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/s41375-021-01204-6","article-title":"Molecular biology of Hodgkin lymphoma","volume":"35","author":"Weniger","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmg.2022.104672_bib74","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1172\/JCI95993","article-title":"Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells","volume":"128","author":"Weniger","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmg.2022.104672_bib75","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1182\/bloodadvances.2019001012","article-title":"Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion","volume":"3","author":"Wienand","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmg.2022.104672_bib76","doi-asserted-by":"crossref","first-page":"188","DOI":"10.15252\/emmm.201708292","article-title":"Loss of RASGRP1 in humans impairs T-cell expansion leading to Epstein-Barr virus susceptibility","volume":"10","author":"Winter","year":"2018","journal-title":"EMBO Mol. Med."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721222002531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721222002531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:54:14Z","timestamp":1761710054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721222002531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1769721222002531"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2022.104672","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An update on molecular features and therapeutic perspectives of pediatric classical Hodgkin Lymphoma. What the clinician needs to know?","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2022.104672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104672"}}